Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 2Unknown 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 1789Neoplasms 1516Carcinoma, Non-Small-Cell Lung 1053Prostatic Neoplasms 965Colorectal Neoplasms 889Lung Neoplasms 809Pancreatic Neoplasms 583Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 540Stomach Neoplasms 523Ovarian Neoplasms 513Neoplasm Metastasis 492Multiple Myeloma 491Recurrence 417Melanoma 390Squamous Cell Carcinoma of Head and Neck 374Uterine Cervical Neoplasms 366Brain Neoplasms 364Head and Neck Neoplasms 355Esophageal Neoplasms 320Precursor Cell Lymphoblastic Leukemia-Lymphoma 313Endometrial Neoplasms 311Lymphoma 309Triple Negative Breast Neoplasms 301Glioblastoma 298Rectal Neoplasms 284Urinary Bladder Neoplasms 268Sarcoma 266Hematologic Neoplasms 266Colonic Neoplasms 257

Interventions

tislelizumab 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Non-squamous Non-small-cell Lung Cancer × Clear all
NCT06416410 2025-04-04

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Allist Pharmaceuticals, Inc.

Phase 3 Recruiting
392 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡